527 related articles for article (PubMed ID: 17963458)
1. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
6. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Mah GT; Mabasa VH; Chow I; Ensom MH
Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
[TBL] [Abstract][Full Text] [Related]
7. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
Thabit AK; Grupper M; Nicolau DP; Kuti JL
J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
[TBL] [Abstract][Full Text] [Related]
8. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
Cies JJ; Jain J; Kuti JL
Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131
[TBL] [Abstract][Full Text] [Related]
11. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
[TBL] [Abstract][Full Text] [Related]
13. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R
J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Frei CR; Burgess DS
Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
[TBL] [Abstract][Full Text] [Related]
17. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
18. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
